2010
DOI: 10.1007/s12185-010-0670-1
|View full text |Cite
|
Sign up to set email alerts
|

Clinical significance of minimal residual disease in adult acute lymphoblastic leukemia

Abstract: .0%) and relapse-free survival (RFS) rate (40.0%) at 2 years in CR patients with MRD level 10 -3 (n=12) were significantly lower than those in CR patients with MRD level <10 -3 (n=15) (OS rate: 79.0%, RFS rate: 79.4%) (log-rank test, P=0.017 and 0.0007). We also applied multicolor flow cytometry for comparison with MRD results analyzed by PCR methods. The comparison of results obtained in 27 follow-up samples showed consistency in 17 samples (63.0%) (P=0.057). MRD analysis on day 100 is important for treatmen… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
8
1

Year Published

2012
2012
2024
2024

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 17 publications
(10 citation statements)
references
References 21 publications
1
8
1
Order By: Relevance
“…39 Similarly, in another small series of both Ph+ and Ph negative patients, the presence of MRD was significant for relapse at day 100 following induction therapy, but not before allogeneic HSCT. 40 …”
Section: Discussionmentioning
confidence: 99%
“…39 Similarly, in another small series of both Ph+ and Ph negative patients, the presence of MRD was significant for relapse at day 100 following induction therapy, but not before allogeneic HSCT. 40 …”
Section: Discussionmentioning
confidence: 99%
“…Samples were amplified by RQ-PCR and quantified by parallel amplification of serial dilutions of transcript-containing plasmids [17,18]. …”
Section: Methodsmentioning
confidence: 99%
“…16 Recurrence or persistence of ALL in BM-as detected by patient-specific PCR-based assays with a sensitivity down to one tumor cell in 10 4 BM cells-is among the most important prognostic predictors for this disease. [22][23][24] Conversion of patients into an MRD-negative status by blinatumomab predicted a positive outcome on long-term leukemia-free survival. 16 In this trial, blinatumomab was continuously infused to patients by a portable mini-pump and port system at a dose level of 15 g/m 2 /d for 4 weeks.…”
Section: Introductionmentioning
confidence: 99%